Charles River signs anticancer gene therapy production deal with Rznomics
Under the partnership, Rznomics will use Charles River’s viral vector CDMO knowledge to begin clinical development of its…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jan 23
Under the partnership, Rznomics will use Charles River’s viral vector CDMO knowledge to begin clinical development of its…
18 Jan 23
Galcanezumab is a monoclonal antibody, which was approved by the US Food and Drug Administration in 2018 for…
06 Jan 23
Novo Nordisk will obtain the right to use Fujifilm Cellular Dynamics’ iPSC platform for research and development and…
04 Jan 23
Gilead will obtain an option to licence EVOQ’s nanodisc technology and exclusive rights to develop and commercialise immunotherapy…
03 Jan 23
Sandoz will acquire the global rights to ALT-B4, derived using Alteogen’s Hybrozyme technology, to develop a subcutaneous version…
22 Dec 22
The decision was based on positive results from the HERIZON-BTC-01 trial in previously treated HER2-amplified biliary tract cancers
21 Dec 22
The binding agreement between the parties is centred on collaborating in four key areas that include localising industries,…
19 Dec 22
The two companies will jointly discover, develop, and commercialise small molecules that modulate novel G protein-coupled receptor (GPCR)…
16 Dec 22
The Chinese biopharmaceutical company will obtain an exclusive right to develop and commercialise Tigulixostat in China, in exchange…
15 Dec 22
The company will acquire ophthalmic drugs including Ilevro, Nevanac, Vigamox, Maxidex, and Triesence from Novartis, in exchange for…